Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 946-953

  Deeks, Steven G ^a,c   Barbour, Jason D ^a,b   Martin, Jeffrey N ^a   Swanson, Melinda S ^a   Grant, Robert M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; VIRUS RNA;

ARTICLE; CORRELATION FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; RNA, VIRAL;

EID: 0034070773     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315334     Document Type: Article

References (33)

1. 1. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-05)43-82.
2. 2. Carpenter CC, Cooper DA, Fischl M, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
3. 3. Gulick R, Mellors J, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998;280:35-41.
4. 4. Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long lasting recovery of CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
5. 5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
6. 6. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353:863-8.
7. 7. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. Virologic outcomes with protease inhibitor therapy in an urban AIDS clinic: relationship between baseline characteristics and response to both initial and salvage therapy. AIDS 1999;13:F35-F44.
8. 8. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
9. 9. Winkelstein W, Jr., Lyman DM, Padian N, et al. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA 1987;257:321-5.
10. 10. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
11. 11. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
12. 12. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variability in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994;169:28-36.
13. 13. Gulick RM, Hu XJ, Fiscus SA, et al. Salvage therapy with saquinavir SGC (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) plus delavirdine (DLV), adefovir dipivoxil (ADV) or both: ACTG 359 [abstract 235]. In: Program and abstracts: 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
14. 14. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669-76.
15. 15. Staszewski S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999;13:951-6.
16. 16. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998;177:40-7.
17. 17. Kaufmann D, Panteleo G, Sudre P, Telenti A. CD4 T cell count in HIV-1 individuals remaining viremic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study [letter]. Lancet 1998;351:723-4.
18. 18. Mezzaroma I, Carlesimo M, Pinter E, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999;13:1187-93.
19. 19. Eron JJ, Benoit SL, Jamsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
20. 20. Lyles R, Munoz A, Bazmi H, et al. Natural history of HIV-1 viremia after seroconversion in the multicenter AIDS Cohort Study [abstract 273]. In: Program and abstracts: 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
21. 21. Lenski RE, May RM. The evolution of virulence in parasites and pathogens: reconciliation between two competing hypotheses. J Theor Biol 1994; 169: 23-265.
22. 22. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271: 1582-6.
23. 23. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-infected humans. Nat Med 1999;5:83-9.
24. 24. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-52.
25. 25. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998;72:3300-6.
26. 26. Stoddart C, Mammano F, Moreno M, et al. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo [abstract 4]. In: Program and abstracts: 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
27. 27. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998;72:3773-8.
28. 28. Kosalaraksa P; Kavlick MF; Maroun V; Le R; Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 1999;73:5356-63.
29. 29. Bonhoeffer S, Coffin JM, Nowak MA. Human immunodeficiency virus drug therapy and virus load. J Virol 1997;71:3275-78.
30. 30. Strack PR, Frey MW, Rizzo CJ, et al. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc Natl Acad Sci USA 1996;93:9571-6.
31. 31. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998;95:13120-4.
32. 32. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999;180:659-65.
33. 33. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999;130:570-77.